Internal Medicine

A topic in the Science corpus, drawn from 324 papers.

Trusted voices in Internal Medicine

Ordered by the trust Internal Medicine's own network concentrates on each researcher, most first.

  1. J. Heit — trusted by 16 researchers here
  2. Peter Carmeliet — trusted by 15 researchers here
  3. Andrew Nicolaides — trusted by 4 researchers here
  4. Gregory Y. H. Lip — trusted by 5 researchers here
  5. N. Mackman — trusted by 5 researchers here
  6. C. Patrono — trusted by 2 researchers here
  7. R. White — trusted by 3 researchers here
  8. A. Adamis — trusted by 3 researchers here
  9. Shu Chien — trusted by 3 researchers here
  10. J. Chiu — trusted by 3 researchers here
  11. N. Ferrara — trusted by 2 researchers here
  12. A. Varki — trusted by 2 researchers here

Most-cited papers in Internal Medicine

Ordered by the recorded citation count from the source corpus; a citation is not an endorsement.

  1. Dabigatran versus warfarin in patients with atrial fibrillation. (2009, New England Journal of Medicine) — 9,875 citations
  2. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. (2010) — 6,747 citations
  3. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) (2019, European Respiratory Journal) — 4,847 citations
  4. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. (2014, Stroke) — 4,662 citations
  5. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. (2012, Chest) — 4,568 citations
  6. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association (2018, Stroke) — 4,363 citations
  7. Angiogenesis in life, disease and medicine (2005, Nature) — 3,551 citations
  8. The Epidemiology of Venous Thromboembolism (2003, Circulation) — 3,241 citations
  9. Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation (2001) — 3,080 citations
  10. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. (2004, Chest) — 2,925 citations
  11. Guidelines for the prevention of intravascular catheter-related infections. (2002, American Journal of Infection Control) — 2,643 citations
  12. Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism (2008) — 2,605 citations
  13. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. (2009, New England Journal of Medicine) — 2,549 citations
  14. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (2012, Chest) — 2,418 citations
  15. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients (2010, Journal of Thrombosis and Haemostasis) — 2,386 citations
  16. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. (2003, New England Journal of Medicine) — 2,379 citations
  17. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. (2000, Archives of Internal Medicine) — 2,284 citations
  18. Oral rivaroxaban for symptomatic venous thromboembolism. (2010, New England Journal of Medicine) — 2,252 citations
  19. Effects of Disturbed Flow on Vascular Endothelium: Pathophysiological Basis and Clinical Perspectives (2011, Physiological Reviews) — 2,222 citations
  20. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up (2020, Journal of the American College of Cardiology) — 2,222 citations
  21. Oral apixaban for the treatment of acute venous thromboembolism. (2013, New England Journal of Medicine) — 2,195 citations
  22. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (2008, Chest) — 2,089 citations
  23. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (2012, Chest) — 2,080 citations
  24. Development and validation of a predictive model for chemotherapy-associated thrombosis. (2008, Blood) — 2,076 citations
  25. Platelet activation and atherothrombosis. (2007, New England Journal of Medicine) — 2,075 citations
  26. Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension: A Scientific Statement From the American Heart Association (2011, Circulation) — 2,052 citations
  27. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (2012, Chest) — 1,996 citations
  28. Revision of the CEAP classification for chronic venous disorders: consensus statement. (2004, Journal of Vascular Surgery) — 1,915 citations
  29. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. (2002, Blood) — 1,875 citations
  30. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. (2004, New England Journal of Medicine) — 1,840 citations
  31. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. (2013, New England Journal of Medicine) — 1,829 citations
  32. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy (2020, Thrombosis Research) — 1,804 citations
  33. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. (2001, Chest) — 1,780 citations
  34. Thrombosis as an intravascular effector of innate immunity (2012, Nature reviews. Immunology) — 1,769 citations
  35. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo (2012, Journal of Experimental Medicine) — 1,763 citations
  36. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. (2012, New England Journal of Medicine) — 1,719 citations
  37. [Oral Rivaroxaban for the treatment of symptomatic pulmonary embolism]. (2013, Revista clínica española (Ed. impresa)) — 1,685 citations
  38. Oral rivaroxaban for symptomatic venous thromboembolism. (2011, New England Journal of Medicine) — 1,683 citations
  39. Derivation of a Simple Clinical Model to Categorize Patients Probability of Pulmonary Embolism: Increasing the Models Utility with the SimpliRED D-dimer (2000) — 1,672 citations
  40. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia (2020, Journal of Thrombosis and Haemostasis) — 1,663 citations
  41. Prognosis of cancers associated with venous thromboembolism. (2000, New England Journal of Medicine) — 1,611 citations
  42. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy (2007, Journal of Thrombosis and Haemostasis) — 1,607 citations
  43. Contribution of platelets to tumour metastasis (2011, Nature Reviews. Cancer) — 1,595 citations
  44. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association… (2008, Circulation) — 1,591 citations
  45. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke… (2006, Stroke) — 1,570 citations
  46. Laboratory haemostasis monitoring in COVID‐19 (2020, Journal of Thrombosis and Haemostasis) — 1,565 citations
  47. Idarucizumab for Dabigatran Reversal. (2015, New England Journal of Medicine) — 1,551 citations
  48. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. (2001, Chest) — 1,534 citations
  49. Risk factors for venous thromboembolism. (2003, Clinics in Chest Medicine) — 1,520 citations
  50. Excluding Pulmonary Embolism at the Bedside without Diagnostic Imaging: Management of Patients with Suspected Pulmonary Embolism Presenting to the Emergency Department by Using a Simple Clinical… (2001, Annals of Internal Medicine) — 1,486 citations

Most active researchers

By papers in this topic: a volume measure, not trust.